Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
August 09, 2024 07:00 ET
|
Legend Biotech USA Inc.
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 millionMHRA and Health Canada approved CARVYKTI® in earlier lines of treatment for adult patients with...
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
August 08, 2024 16:05 ET
|
Legend Biotech USA Inc.
SOMERSET, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Peter Salovey,...
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
July 26, 2024 07:00 ET
|
Legend Biotech USA Inc.
SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial...
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
July 10, 2024 08:00 ET
|
Legend Biotech USA Inc.
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET...
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
July 02, 2024 08:00 ET
|
Legend Biotech USA Inc.
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from...